Health officials in Sweden have suspended the use of the Moderna Vaccine for anyone under the age of 31 indefinitely according to the U.K. Daily Mail. This follows along with other countries such as Finland, Iceland, and Denmark
There is data suggesting that young men who receive the Moderna shot are at increased risk for “myocarditis, an inflammation of the heart muscle, and pericarditis, an inflammation of the sac around the heart.”
The Daily Mail noted a study that has not yet been peer-reviewed concluded that “young males under [age] 20 are up to six times more likely to develop myocarditis after contracting COVID-19 than those who have been vaccinated.” The decision by Sweden comes after the US FDA has put the Moderna plans for shots for 12–17-year-olds on hold. The CDC however has approved boosters for the Moderna and Johnson & Johnson vaccines.
Dr. Tom Shimabukuro, the Deputy Director of the H1N1 Vaccine Task Force at the Centers for Disease Control, said “There is an increased risk of myocarditis and pericarditis with either the Moderna or Pfizer vaccine, in particular after the second dose of the vaccines.”
The Daily Mail reported on the data showing “the risk was 13 times greater for those getting the Moderna vaccine than for those who got the Pfizer vaccine.”
Sweden’s Public Health Agency said the unpublished data linking the Moderna vaccine with the heart conditions means there is “an increased risk of side effects such as inflammation of the heart muscle or the pericardium.” However, they also say that “The risk of being affected is very small.” Additionally, that data has not been publicly released.
The FDA said, “The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age”, and that “some individuals required intensive care support”. The FDA also notes that long-term information about the risks is not yet available.
Be sure to check back with the ABN Blog regularly